Green Cross Medical Science Corporation Total Assets
Green Cross Medical Science Corporation total assets. Based on the latest financial reports, Green Cross Medical Science Corporation (142280) holds total assets worth ₩96.94 Billion KRW (≈ $65.70 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 142280 stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Green Cross Medical Science Corporation (2014–2025)
Total assets of Green Cross Medical Science Corporation from 2014 to 2025. This chart illustrates how Green Cross Medical Science Corporation's total assets have evolved over time, based on quarterly financial data. See Green Cross Medical Science Corporation share price for real-time trading data and today's change.
Green Cross Medical Science Corporation - Asset Composition Analysis
Green Cross Medical Science Corporation Total Assets Breakdown (December 2025)
Green Cross Medical Science Corporation total assets breakdown as of December 2025. Green Cross Medical Science Corporation's total assets of ₩96.94 Billion consist of 45.0% current assets and 55.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.4% |
| Accounts Receivable | ₩21.06 Billion | 23.3% |
| Inventory | ₩17.45 Billion | 19.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩483.93 Million | 0.5% |
| Goodwill | ₩253.76 Million | 0.3% |
Asset Composition Trend (2014–2025)
This chart illustrates how Green Cross Medical Science Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Green Cross Medical Science Corporation's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Green Cross Medical Science Corporation's current assets represent 45.0% of total assets in 2025, a decrease from 76.4% in 2014.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2025, down from 0.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 23.3% of total assets.
Green Cross Medical Science Corporation Competitors by Total Assets
Key competitors of Green Cross Medical Science Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Green Cross Medical Science Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.47 | 1.06 | 1.37 |
| Quick Ratio | 0.84 | 0.68 | 0.76 |
| Cash Ratio | 0.00 | 0.00 | 0.05 |
| Working Capital | ₩15.05 Billion | ₩2.95 Billion | ₩21.43 Billion |
Green Cross Medical Science Corporation - Advanced Valuation Insights
This section examines the relationship between Green Cross Medical Science Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.25 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.9% |
| Total Assets | ₩90.51 Billion |
| Market Capitalization | $42.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Green Cross Medical Science Corporation's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Green Cross Medical Science Corporation's assets grew by 2.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Green Cross Medical Science Corporation (2014–2025)
The table below shows the annual total assets of Green Cross Medical Science Corporation from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩90.51 Billion ≈ $61.34 Million |
+2.88% |
| 2024-12-31 | ₩87.97 Billion ≈ $59.62 Million |
-2.82% |
| 2023-12-31 | ₩90.53 Billion ≈ $61.35 Million |
-6.16% |
| 2022-12-31 | ₩96.47 Billion ≈ $65.38 Million |
+0.88% |
| 2021-12-31 | ₩95.63 Billion ≈ $64.81 Million |
-9.44% |
| 2020-12-31 | ₩105.60 Billion ≈ $71.57 Million |
+18.83% |
| 2019-12-31 | ₩88.87 Billion ≈ $60.22 Million |
+38.91% |
| 2018-12-31 | ₩63.97 Billion ≈ $43.35 Million |
+5.67% |
| 2017-12-31 | ₩60.54 Billion ≈ $41.03 Million |
-4.81% |
| 2016-12-31 | ₩63.61 Billion ≈ $43.10 Million |
-12.40% |
| 2015-12-31 | ₩72.61 Billion ≈ $49.21 Million |
+39.37% |
| 2014-12-31 | ₩52.10 Billion ≈ $35.31 Million |
-- |
About Green Cross Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CER… Read more